RxDoctor Payments Data

Tatvam Choksi, MD

Internal Medicine · Chicago, ILNPI 1770839987

Payments from drug & device makers

$1,063in general payments, 2019–2025

Across 16 payments — averaging $66.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$267
  • Heartflow, Inc.$148
  • Actelion Pharmaceuticals US, Inc.$145
  • Bayer$140
  • Philips North America LLC$125
  • Medtronic$92
  • plus $146 from 6 others

What the payments were for

  • Food & beverage$82578%
  • Education$23822%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,063 in reported general payments places this provider in the 75th percentile of 5,182 internal medicine providers in Illinois.

See all internal medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$84,669
Medicare patients
157
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban80$19,375
XareltoRivaroxaban64$11,722
JardianceEmpagliflozin38$8,945
EntrestoSacubitril/Valsartan40$7,328
JanuviaSitagliptin Phosphate44$6,412
FarxigaDapagliflozin Propanediol33$4,826
Enoxaparin Sodium16$1,351
Levetiracetam98$1,070
Sevelamer Carbonate35$1,048
Atorvastatin Calcium184$966
Metoprolol Succinate141$841
Tamsulosin Hcl156$810
Naloxone Hcl12$758
Lidocaine11$688
Pantoprazole Sodium136$479

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$22$19,37580 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 5,182 internal medicine providers in Illinois.

Other internal medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →